Providence Therapeutic Holdings and Ontario Institute for Cancer Research Announce Landmark Collaboration for mRNA Drug Discovery and Development

24 May 2024 | Friday | News

Innovative partnership combines OICR's cancer genomics expertise with Providence's cutting-edge mRNA technology to accelerate preclinical drug development and launch new clinical oncology initiatives, ensuring affordable access for Canadians.
Image Source : Public Domain

Image Source : Public Domain

Providence Therapeutic Holdings Inc. ("Providence"), a messenger RNA (mRNA) and lipid nanoparticle platform company engaged in the development of vaccines and therapeutics, and the Ontario Institute for Cancer Research (OICR), Ontario's largest publicly funded cancer research institute delivering real-world solutions to people affected by cancer, today announced the signing of a collaboration agreement for mRNA drug discovery and development. This is a unique collaboration that combines OICR's expertise in cancer genomics and translational drug discovery with Providence's next generation of mRNA and LNP technology to accelerate preclinical drug development and launch new clinical initiatives that answer key questions in clinical oncology.

"OICR and Providence share a common vision of advancing research in cancer prevention and treatment in Ontario, across Canada, and globally. We look forward to leveraging Providence's next generation mRNA and LNP platform technology and drug development expertise alongside the experts at OICR to improve the lives of people battling cancer," said Brad Sorenson, CEO and Founder of Providence Therapeutics.

"Partnering with an mRNA industry leader like Providence will help OICR harness our strengths in bioinformatics, genomics and immunology to generate new and exciting ways to prevent and treat cancer," says Dr. Laszlo Radvanyi, President and Scientific Director of OICR. "I am especially excited for the impact this partnership will have for people affected by cancer as well as the potential economic value it can bring in helping drive Canada's leadership in this rapidly growing field."

OICR and Providence's partnership will help advance modern drug development in Canada and create new clinical initiatives that will touch the lives of people across the country. As product development and manufacturing will be done domestically, Canadians will be first in line to participate in new clinical oncology programs and access new treatments.

All programs that emerge from this strategic partnership will result in guaranteed country-of-origin rights to Canada that will ensure Canadians will have affordable access to any medicines created.


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in